{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:31Z","timestamp":1788306571674,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2019.07.021","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T08:24:28Z","timestamp":1563438268000},"page":"4858-4863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered concomitantly with the meningococcal serogroup B (4CMenB) vaccine in infants: A post-hoc analysis in a phase 3b, randomised, controlled trial"],"prefix":"10.1016","volume":"37","author":[{"given":"Marco Aurelio P.","family":"Safadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-581X","authenticated-orcid":false,"given":"Federico","family":"Martinon-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily Yin","family":"Weckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Junior","given":"Edson Duarte","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Jorge","family":"da Fonseca Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6944-4249","authenticated-orcid":false,"given":"Arnold","family":"Willemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Ahsan","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Borys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.07.021_b0005","unstructured":"World Health Organization Pneumonia Fact Sheet 2016. Available at http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/pneumonia. Last accessed: 25 June 2018."},{"key":"10.1016\/j.vaccine.2019.07.021_b0010","unstructured":"World Health Organization Pneumococcal vaccines WHO position paper. Wkly Epidemiol Rec. 2012;87:129-44."},{"key":"10.1016\/j.vaccine.2019.07.021_b0015","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/14760584.2018.1516551","article-title":"Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience","volume":"17","author":"Mrkvan","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.07.021_b0020","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/cid\/ciu524","article-title":"Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality","volume":"59","author":"Harboe","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.021_b0025","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1016\/j.vaccine.2017.09.005","article-title":"The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: a systematic review and meta-analysis","volume":"35","author":"Alicino","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.021_b0030","doi-asserted-by":"crossref","first-page":"e0183191","DOI":"10.1371\/journal.pone.0183191","article-title":"Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7\u201359 months. A matched case-control study","volume":"12","author":"Dominguez","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.07.021_b0035","doi-asserted-by":"crossref","first-page":"591580","DOI":"10.1155\/2015\/591580","article-title":"Impacts of the 13-valent pneumococcal conjugate vaccine in children","volume":"2015","author":"Esposito","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.vaccine.2019.07.021_b0040","unstructured":"World Health Organization. Immunization coverage. Available at http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/immunization-coverage. Last accessed: 25 Oct 2018."},{"key":"10.1016\/j.vaccine.2019.07.021_b0045","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(12)61187-8","article-title":"Effect of vaccines on bacterial meningitis worldwide","volume":"380","author":"McIntyre","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.07.021_b0050","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S2352-4642(18)30113-5","article-title":"Life-threatening infections in children in Europe (the EUCLIDS Project): a prospective cohort study","volume":"2","author":"Martinon-Torres","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2019.07.021_b0055","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.021_b0060","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2019.07.021_b0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14760584.2019.1557520","article-title":"The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations","volume":"18","author":"Acevedo","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.07.021_b0070","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","author":"Medini","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.021_b0075","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.vaccine.2017.05.023","article-title":"Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: immunogenicity and safety results from a randomised open-label phase 3b trial","volume":"35","author":"Martin\u00f3n-Torres","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.021_b0080","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.07.021_b0085","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.vaccine.2017.03.002","article-title":"Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: a phase 3b, randomized controlled trial","volume":"35","author":"Safadi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.021_b0090","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.vaccine.2019.03.011","article-title":"Comparison between a new multiplex electrochemiluminescence assay and the WHO reference enzyme-linked immunosorbent assay to measure serum antibodies against pneumococcal serotype-specific polysaccharides","volume":"37","author":"Feyssaguet","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.021_b0095","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1309\/LMCH-C4Q2-VFL9-3T1A","article-title":"A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides","volume":"117","author":"Pickering","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.vaccine.2019.07.021_b0100","unstructured":"World Health Organization. Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA) (007sp Version). Available at https:\/\/www.vaccine.uab.edu\/uploads\/mdocs\/ELISAProtocol(007sp).pdf. Last accessed: 15 May 2019."},{"key":"10.1016\/j.vaccine.2019.07.021_b0105","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/S0264-410X(03)00230-5","article-title":"Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants","volume":"21","author":"Jodar","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.021_b0110","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/CVI.13.3.356-360.2006","article-title":"Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera","volume":"13","author":"Henckaerts","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.07.021_b0115","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jped.2014.07.002","article-title":"Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine","volume":"91","author":"Hirose","year":"2015","journal-title":"J Pediatr (Rio J)"},{"key":"10.1016\/j.vaccine.2019.07.021_b0120","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1097\/INF.0b013e318199f609","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines","volume":"28","author":"Wysocki","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.07.021_b0125","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1016\/j.vaccine.2016.04.006","article-title":"Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program","volume":"34","author":"Moreira","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.021_b0130","unstructured":"Ministry of Health Brazil. Information note 149\/2015. Available at http:\/\/www.aids.gov.br\/pt-br\/legislacao\/nota-informativa-no-1492015. Last accessed: 15 May 2019."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19309120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19309120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:34:46Z","timestamp":1759401286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19309120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":26,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X19309120"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered concomitantly with the meningococcal serogroup B (4CMenB) vaccine in infants: A post-hoc analysis in a phase 3b, randomised, controlled trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}